| |
[摘要]：Dengue represents a major, growing public health problem, with an estimated of 2.5 billion people at risk of infection and about 50 million cases. Vector control is the only way of controlling dengue transmission; however, in spite of efforts, an expanded geographic extension of the vector and viruses is observed. Consequently, there is an urgent need for a safe and effective dengue vaccine. Currently, there is no licensed vaccine available, although there are several candidates in different stages of development, a few highly promising. Strategies that have been followed include inactivated viruses, conventional live attenuated vaccines, chimeric live attenuated vaccines, DNA, subunit and vectored vaccines. Advances and challenges of dengue vaccine development are updated here. |
|
